Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Oryzon Genomics SA (ORYN) Stock Price & Analysis

ORYN Stock Chart & Stats

MX$52.96MX$0.00(0.00%)
At close:
No data to display
Day’s Range
MXN 52.96 - MXN 52.96
52-Week Range
MXN 48.59 - MXN 52.96
Previous Close
MXN 52.96
Volume
0
Average Volume (3M)
0
Market Cap
MXN 4.19B
Enterprise Value
MXN 230.85M
Total Cash (Recent Filing)
MXN 22.12M
Total Debt (Recent Filing)
MXN 7.10M
Price to Earnings (P/E)
―
Beta
0.02
Next Earnings
Mar 04, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Proprietary Epigenetics Focus

Oryzon’s proprietary epigenetic approach gives it a defined scientific platform aimed at oncology and CNS disorders with high unmet need. If clinical development succeeds, this focused technology base could support multiple therapies and create durable differentiation beyond a single candidate.

Modest Leverage

Low leverage provides greater financial flexibility than a heavily indebted development-stage biotech. With relatively limited debt obligations, Oryzon may have more capacity to fund research, manage clinical development volatility, and pursue strategic options without excessive refinancing pressure.

Growing Equity Base

Meaningful growth in total assets and equity strengthens the company’s financial foundation while its pipeline remains in development. A larger equity base can provide additional capacity to sustain research programs and absorb the long timelines inherent in clinical-stage biotechnology.

Bears Say

Persistent Unprofitability

Oryzon has not yet demonstrated a profitable operating model, as recurring operating and net losses continue to exceed any gross profit generated. This keeps the company dependent on external capital or future commercialization success to support its long-term development strategy.

Volatile Revenue Base

Repeated periods of zero revenue indicate that Oryzon lacks a stable commercial revenue base and remains reliant on irregular or non-recurring sources. This volatility makes financial planning less predictable and leaves future funding needs closely tied to pipeline progress and potential partnerships.

Ongoing Cash Burn

Persistent negative operating and free cash flow shows that the business does not yet fund its own operations or development activities. Continued cash burn can require additional financing over time, potentially increasing dilution or limiting the pace and breadth of clinical investment.

Oryzon Genomics SA News

ORYN FAQ

What was Oryzon Genomics SA’s price range in the past 12 months?
Oryzon Genomics SA lowest stock price was Mex$48.59 and its highest was Mex$52.96 in the past 12 months.
What is Oryzon Genomics SA’s market cap?
Oryzon Genomics SA’s market cap is Mex$4.19B.
When is Oryzon Genomics SA’s upcoming earnings report date?
Oryzon Genomics SA’s next earnings report is estimated for Oct 22, 2026 (not yet confirmed), which is 10 days ago.
How were Oryzon Genomics SA’s earnings last quarter?
Oryzon Genomics SA released its earnings results on Jul 27, 2026. The company reported Mex$0 earnings per share for the quarter, beating the consensus estimate of -Mex$1.179 by Mex$1.179.
Is Oryzon Genomics SA overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Oryzon Genomics SA pay dividends?
Oryzon Genomics SA does not currently pay dividends.
What is Oryzon Genomics SA’s EPS estimate?
Oryzon Genomics SA’s EPS estimate is -1.39.
How many shares outstanding does Oryzon Genomics SA have?
Oryzon Genomics SA has 84,332,150 shares outstanding.
What happened to Oryzon Genomics SA’s price movement after its last earnings report?
Oryzon Genomics SA reported an EPS of Mex$0 in its last earnings report, beating expectations of -Mex$1.179. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Oryzon Genomics SA?
Currently, no hedge funds are holding shares in MX:ORYN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology